Cytokinetics (CYTK) Projected to Release Earnings on Wednesday

Posted by Stanley Muller on Oct 28th, 2026

Cytokinetics (NASDAQ:CYTK – Get Free Report) is expected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($1.44) per share and revenue of $41.20 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. The company’s revenue was down 57.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.12) earnings per share. On average, analysts expect Cytokinetics to post ($5.97) EPS for the current fiscal year and ($4.65) EPS for the next fiscal year.

Cytokinetics Trading Up 1.3%

Shares of Cytokinetics stock opened at $61.52 on Wednesday. The stock has a 50 day moving average of $68.37 and a 200 day moving average of $70.08. Cytokinetics has a fifty-two week low of $58.05 and a fifty-two week high of $88.31.

Analyst Ratings Changes

CYTK has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a report on Friday, September 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Thursday, October 15th. William Blair initiated coverage on shares of Cytokinetics in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. Barclays increased their target price on shares of Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research report on Friday, August 7th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus price target of $105.44.

Get Our Latest Report on Cytokinetics

Insider Buying and Selling

In related news, Director Robert Landry sold 1,000 shares of Cytokinetics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $72.13, for a total value of $72,130.00. Following the completion of the transaction, the director owned 8,184 shares in the company, valued at $590,311.92. The trade was a 10.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the stock in a transaction on Monday, October 12th. The shares were sold at an average price of $62.88, for a total value of $471,600.00. Following the completion of the transaction, the chief executive officer directly owned 278,544 shares in the company, valued at $17,514,846.72. This trade represents a 2.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 183,926 shares of company stock worth $12,937,330. Company insiders own 2.60% of the company’s stock.

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.